What the FDA labels say about taking them together
Lisinopril and sacubitril/valsartan
Lisinopril's FDA label of January 2, 2025 names sacubitril/valsartan in its contraindications section; sacubitril/valsartan's label does not name lisinopril itself but warns about its class (ACE inhibitors). The lisinopril label: “Do not administer QBRELIS within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor.”
Check it at the source: the lisinopril FDA label on DailyMed (effective January 2, 2025, Upsher-Smith Laboratories, LLC); the sacubitril/valsartan FDA label on DailyMed (effective July 6, 2026, Novartis Pharmaceuticals Corporation).
What does the lisinopril label say about sacubitril/valsartan?
Lisinopril label, contraindicationsDo not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [ see Warnings and Precautions (5.2)].
Source: FDA drug label (Qbrelis, NDA208401), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set 9f6e4e57-a489-4b36-b093-b93865d3717c), via openFDA
Source: FDA drug label (Zestril), NDA019777 (Twi Pharms), as published by Upsher-Smith Laboratories, LLC, effective January 2, 2025 (SPL set 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8), via openFDA; the full label on DailyMed
What does the sacubitril/valsartan label say about lisinopril?
Sacubitril/valsartan's label does not name lisinopril itself; it warns about its class (ACE inhibitors):
Sacubitril/valsartan label, contraindicationsCONTRAINDICATIONS ENTRESTO is contraindicated: in patients with hypersensitivity to any component in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)] with concomitant use of ACE inhibitors.
Sacubitril/valsartan label, drug interactionsBlockade of the Renin-Angiotensin-Aldosterone System Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)].
Source: FDA drug label (ENTRESTO), Novartis Pharmaceuticals Corporation, effective July 6, 2026 (SPL set 000dc81d-ab91-450c-8eae-8eb74e72296f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lisinopril | Sacubitril/valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart attack and coronary artery disease, Heart failure | Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0254 per tablet 20 mg tablet | $0.533 per unit 49-51 mg |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once